D&E material - Large Biopsy 3-6 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Tissue after curettage/evacuation.

₹666₹951

30% OFF

D&E Material - Large Biopsy 3-6 cm

Why is it done?
- Dilation & Evacuation (D&E) material collection and histopathological examination of large tissue specimens measuring 3-6 cm obtained during gynecological procedures
- Diagnostic evaluation of intrauterine lesions, abnormal endometrial tissue, or suspicious growths requiring tissue-level analysis
- Detection and characterization of endometrial pathology including hyperplasia, malignancy, polyps, fibroids, and other uterine abnormalities
- Evaluation of abnormal uterine bleeding, post-menopausal bleeding, or persistent vaginal bleeding unresponsive to conservative treatment
- Assessment of endometrial thickness abnormalities identified on imaging studies (ultrasound or MRI)
- Screening and surveillance in high-risk patients (diabetes, obesity, tamoxifen use, family history of gynecological malignancy)
- Typically performed during office-based D&E procedures or therapeutic evacuation procedures requiring comprehensive tissue analysis
Normal Range
- Normal Result: Benign endometrial tissue with no evidence of malignancy, hyperplasia, or significant pathology
- Specimen Size: 3-6 cm tissue fragment (appropriate size for comprehensive microscopic evaluation)
- Normal Histology: Intact endometrial glands and stroma appropriate for menstrual cycle phase; no increased cellularity or architectural distortion
- Negative for malignancy: No carcinoma, sarcoma, or other malignant neoplasms identified
- Negative for hyperplasia: No simple or complex endometrial hyperplasia without or with atypia
- Interpretation Scale: Benign, Atypical (requires follow-up), or Malignant based on histopathological findings
Interpretation
- Benign Findings:
  - Endometrial polyps, fibroids, or normal endometrial tissue - no treatment required; follow-up based on clinical presentation
  - Non-atypical endometrial hyperplasia - may warrant therapeutic intervention including hormonal management
- Atypical Findings:
  - Atypical endometrial hyperplasia - carries increased malignancy risk (8-30%); requires close follow-up and possible hysterectomy consideration
  - Borderline changes - may require repeat sampling and clinical correlation
- Malignant Findings:
  - Endometrial adenocarcinoma or other malignancy - requires urgent staging (imaging, tumor markers) and oncologic consultation
  - Grade and stage determination guides treatment planning (hysterectomy, chemotherapy, radiation therapy)
- Factors Affecting Interpretation:
  - Menstrual cycle phase - affects endometrial appearance and thickness interpretation
  - Hormonal therapy use - may alter histological patterns and cellular architecture
  - Specimen adequacy and fixation - improper handling may affect diagnostic accuracy
  - Infectious processes or inflammation - may obscure or mimic pathology
Associated Organs
- Primary Organ Systems:
  - Uterus (endometrium) - primary target organ for tissue collection and analysis
  - Reproductive tract - includes cervix and vagina as procedural access points
- Conditions Detected:
  - Endometrial adenocarcinoma - most common gynecologic malignancy
  - Endometrial hyperplasia (simple, complex, atypical) - precancerous lesions
  - Endometrial polyps - benign growths causing abnormal bleeding
  - Uterine fibroids/leiomyomas - benign smooth muscle tumors
  - Endometritis - inflammatory/infectious conditions of endometrium
  - Endometrial sarcoma - rare malignant mesenchymal tumors
- Potential Complications with Abnormal Results:
  - Metastatic disease - malignant findings may indicate extrauterine spread requiring extensive workup
  - Recurrence risk - atypical hyperplasia or early-stage malignancy carries significant recurrence potential
  - Treatment morbidity - surgical intervention (hysterectomy) carries procedural and anesthetic risks
  - Systemic complications - advanced malignancy may cause constitutional symptoms and organ dysfunction
Follow-up Tests
- For Benign Findings:
  - Clinical follow-up - monitor for symptom resolution and abnormal bleeding recurrence
  - Repeat ultrasound - as clinically indicated if endometrial thickness abnormalities persist
  - Routine gynecologic surveillance - annual exams and age-appropriate cancer screening
- For Atypical Hyperplasia:
  - Gynecologic/oncologic consultation - urgent evaluation for treatment planning
  - Repeat endometrial biopsy or curettage - within 3-6 months to reassess endometrial changes
  - Pelvic ultrasound or MRI - to assess uterine anatomy and rule out concurrent malignancy
  - Consideration of hysterectomy - definitive treatment in appropriate candidates
- For Malignancy:
  - Urgent gynecologic oncology consultation - within 1-2 weeks for staging and treatment planning
  - CT chest/abdomen/pelvis or MRI - to evaluate for metastatic disease and surgical candidacy
  - Tumor markers - CA-125, CEA as indicated for baseline and surveillance
  - Surgical staging - total abdominal hysterectomy, bilateral salpingo-oophorectomy with lymph node assessment
  - Chemotherapy/radiation - based on histologic grade, stage, and lymph node status
  - Molecular testing - ER/PR status, MSI/MMR, Lynch syndrome screening if indicated
  - Long-term surveillance - imaging and clinical evaluation every 3-6 months for first 2-3 years
- Complementary Tests:
  - Immunohistochemical staining - ER, PR, p53, MSH2, MSH6 for prognostic and therapeutic guidance
  - Genetic counseling and Lynch syndrome testing - if indicated by pathology or family history
Fasting Required?
- Fasting Required: No
- The D&E material collection is a tissue biopsy procedure performed under anesthesia/sedation and does not require fasting from food or fluids
- Pre-Procedure Preparation:
  - NPO (Nothing by Mouth) status - typically 6-8 hours before procedure if general anesthesia planned, per anesthesia guidelines
  - Avoid anticoagulants - discontinue warfarin, DOACs, and NSAIDs 3-5 days before procedure; aspirin use per physician direction
  - Medication review - notify provider of all current medications; some may need temporary discontinuation
  - Pregnancy testing - confirmed negative pregnancy status required before procedure
  - Infection screening - assess for active pelvic infections or cervicitis; may require treatment before procedure
  - Menstrual cycle timing - ideally performed after menses but before ovulation (follicular phase) when feasible
  - Arrange transportation - patient should not drive after sedation/anesthesia; must have responsible adult accompany
  - Informed consent - thorough discussion of risks, benefits, and alternatives; procedure-specific consent form signature
- Post-Procedure Instructions:
  - Activity restrictions - light activity only for 24-48 hours; avoid strenuous exercise, heavy lifting
  - Sexual intercourse avoidance - abstain for 1-2 weeks or as directed to prevent infection
  - Menstrual bleeding - expect spotting and cramping for 24-72 hours; heavy bleeding warrants medical evaluation
  - Tampon use avoidance - use sanitary pads instead for first 2 weeks to reduce infection risk
  - Pain management - acetaminophen or ibuprofen as needed for cramping; avoid aspirin if bleeding occurs

How our test process works!